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Background: People who inject drugs (PWID) are a key population affected by HIV. We assessed the effectiveness
of HIV treatment among a clinical cohort of people living with HIV (PLHIV) diagnosed and referred for community-based
antiretroviral therapy (ART) in Victoria, Australia.
Methods: HIV notification data from a central statewide registry were matched with HIV clinical data from two large HIV
treatment centers in Melbourne. We used survival analysis and Cox proportional hazard models to estimate time to AIDS
and death for PWID in HIV treatment, compared with non-injectors, in the period 1996 – 2008.
Results: Of the 871 individuals, 93 (10.8%) had injecting as an exposure category and 671 (86%) had ever commenced
ART. Adjusted analysis showed younger age, high initial CD4 cell count (>500 cells/mm3) or ever having a CD4 cell
count >500/mm3, and more recent calendar year of ART commencement were all associated with reduced hazards for
AIDS and death, while older age, low initial CD4 cell count (<200/mm3), ever having a CD4 count <200/mm3 (before or
during treatment) and high initial viral load (>5 log10) were associated with increased risk of AIDS and death. PWID
were no more likely to experience AIDS (HR 0.98[0.54 – 1.80]) or death (HR 0.78 [0.18 – 3.42]) than non-injectors.
Conclusion: Survival of HIV-infected PWID on HIV treatment was equivalent to non-injectors. CD4 cell count, initial viral
load, calendar year of commencing ART and age are more important determinants of AIDS and mortality than injecting
status for in-treatment PLHIV in Victoria, Australia.
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People who inject drugs (PWID) are a key population af-
fected by HIV [1]. In Australia the prevalence of HIV
among PWID has remained steady at around 1 – 2%
since the mid 1980s [2]. Around 70% of HIV diagnoses
in Australia are attributed to male-to-male sexual con-
tact, while just over 9% are attributed to heterosexual
sexual contact. Approximately 3% of HIV diagnoses in
Australia are attributed solely to injecting drug use; this
proportion has remained steady since the early 1990s [3,4].
While the proportion of diagnoses attributable only to
injecting drug use remains low, individuals are often in
more than one risk population for HIV acquisition, such as
men who have sex with men (MSM) and PWID. When
including grouping for multiple exposure categories, the* Correspondence: nicktropical@yahoo.com
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unless otherwise stated.proportion of HIV diagnoses in Australia with injecting as
an exposure category increases to almost 8% [3].
While the effectiveness of HIV treatment with anti-
retroviral therapy (ART) has improved substantially over
the last 15 years, since the advent of highly active anti-
retroviral therapy (HAART) to the point where an HIV
diagnosis may not markedly reduce life expectancy [5],
PWID in many countries, especially low- and middle-
income countries, continue to have poorer access to and
outcomes from HIV treatment compared with their non-
injecting peers, even when adherence is taken into ac-
count [6,7]. Nevertheless, there is growing evidence that
with appropriate support, PWID can achieve good clinical
outcomes during HIV treatment [8-11].
To date, no studies have examined HIV treatment
among PWID in Australia, a low HIV prevalence country
with a State-supported universal health care system and
an early and strong public health response to HIV [12].
The current study assesses the effectiveness of HIVThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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HIV (PLHIV) diagnosed and treated in Victoria, Australia,
to determine the effectiveness of HIV treatment for PWID
in the post-HAART era.Figure 1 Data management flow.Methods
HIV is a notifiable disease in Australia. In Victoria, HIV
diagnoses are recorded in a central registry. Demographic
and risk group data are recorded at diagnosis. This is peri-
odically updated. Death in a person with HIV is also notifi-
able to the central HIV registry in addition to the civil
registry of deaths.
We matched notification data of HIV diagnoses with
clinical data from patients attending the Alfred Hospital
HIV treatment clinic (the Victorian HIV/AIDS Service -
VAHS) and the Melbourne Sexual Health Centre (MSHC)
for HIV treatment. The vast majority of the approximately
4,000 PLHIV in Victoria live in Melbourne. These two
sites were chosen as they treat a large proportion of
PLHIV seeking treatment in Victoria. For example, our
dataset contained 35% of all people diagnosed with
HIV in Victoria between 1996 and 2005. As clinical data
of interest was from the time period between 1996 and
2008 i.e. post-HAART, individuals were included where
first contact with the treatment service (VHAS or MSHC)
was between 1996 and 2008 and having had an HIV
diagnosis prior to 2007. Records were matched using
universal medical record numbers (where available) or
name codes combined with date of birth and gender.
Matching of the Victorian HIV Registry and the Alfred
Hospital HIV treatment clinic generated 2,720 individ-
ual matches and eight duplicates. Matching of the
Victorian HIV Registry and the Melbourne Sexual
Health Centre HIV clinical data provided an additional
58 individuals. Merging these matched datasets resulted
in clinical data being available for 2,868 individuals after
records where individuals were aged < 13 were deleted
from the dataset. A numerical individual identifier was
generated for each case/patient and other identifying
information removed.
Data on exposure category for HIV acquisition was
taken from the Victorian HIV registry. Exposure categor-
ies included injecting, male-to-male sex, heterosexual
sex or unknown. Where more than one exposure was
present, both were recorded, e.g. an individual could
have both injecting drug use and male-to-male sex as
exposures for HIV. Mortality data was recorded in
both the Alfred Hospital dataset and the Victorian
HIV registry. Death was accepted if it occurred in
either dataset. We examined completeness and found
consistency between the datasets (data not reported).
Data for AIDS diagnosis and other clinical data were
recorded consistently in the Alfred and MSHCdatasets and inconsistently in the Victorian HIV regis-
try. Therefore, clinical data was only derived from the
Alfred Hospital and MSHC datasets. Data management
following matching and deduplication is shown in
Figure 1.Variables of interest
Demographic characteristics included age, gender, indi-
genous status and country of birth. The single individual
identified as transgender was included in the male cat-
egory for the purposes of analysis. Risk group classification
was derived from exposure category for HIV transmis-
sion at HIV diagnosis and categorized as PWID or
non-injector, MSM or heterosexual, including belong-
ing to more than one risk group. First recorded CD4
or viral load test result was referred to as ‘initial’
result. AIDS diagnosis was defined as date of first
recorded AIDS defining illness. Mortality data were
recorded.Analysis
Characteristics of the baseline study population were com-
pared using the Pearson x2 test for dichotomous variables,
the student’s t-test or Wilcoxon rank-sum test for con-
tinuous variables. Time points during HIV diagnosis were
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vice (either the VAHS or MSHC) and date of initiation of
HIV treatment. Age at diagnosis, age at contact with the
treatment service or age at commencement of HIV treat-
ment were categorized into groups based on the distribu-
tion of ages in the dataset. CD4 cell count and viral load
were dichotomized and categorized based on commonly
used categories. For CD4, this was 0 – 199, 200 – 349,
350 – 499 and > 500 cells/mm3. For viral load, this was
0 – 3.99 log10, 4 – 4.99 log10 and ≥5 log10. In the sur-
vival analysis we examined only those individuals who
ever commenced ART (n = 758, though only 687 had
data on injecting status). Failure in the survival analysis
was defined as AIDS defining illness diagnosis (first re-
corded) or death; otherwise records were censored at
the last recorded contact with the treatment service.
The time unit for all analyses was days from HIV diag-
nosis. The analysis for AIDS included 603 individuals,
with a mean time at risk of 1,482 days (~3 years and
10 months). There were 108 failures (AIDS diagnoses).
The analysis for death included 687 individuals, with a
mean time at risk of 2,694 days (7 years 4 months and
15 days). There were 47 failures (deaths). Adjusted and
unadjusted analyses were performed using death and
AIDS separately. Variables achieving p < 0.1 in unadjusted
analysis were included in Cox Proportional Hazards ad-
justed models, with the exception of PWID, given the a
priori centrality to the hypothesis. For calendar year of ini-
tiation of HIV treatment, HIV diagnosis and first contact
with the treatment service, years were grouped into three-
year periods due to the low number of individuals ever
having commenced HIV treatment.
Ethics approval for the study was provided by the
Victorian Department of Human Services Human Research
Ethics Committee and the Alfred Hospital Human Research
Ethics Committee. Data were analyzed using Stata 11
(StataCorp, College Station, TX, USA).
Results
Table 1 illustrates baseline characteristics of study par-
ticipants stratified by history of injecting drug use. There
were 918 individuals included in the final analysis, of
which 871 had a recorded exposure category for HIV ac-
quisition, including 628 (79.4%) MSM and 93 (10.8%)
PWID. PWID were significantly younger than non-injectors,
while the gender distribution was consistent between the
groups. Females accounted for around 11% in both groups.
There were no differences between PWID and non-injectors
in initial CD4 cell count (362 vs 365.5 cells/mm3 p = 0.51)
or initial viral load (27,150 vs 34,100 copies p = 0.79). There
were also no differences in the median number of CD4
count tests or viral load tests between patients with a history
of injecting drug use and those with no history. Of the 687
individuals who had ever commenced ART, 620 (90.2%) hadno history of injecting drug use and 67 (9.8%) had a history
of injecting drug use. Overall, AIDS and death were propor-
tionally more common in non-injectors compared with
PWID. Of those that had ever commenced ART, AIDS was
more common in non-injectors, while there was no differ-
ence in the proportion of deaths comparing PWID with
non-injectors.
Table 2 shows adjusted and unadjusted Cox Propor-
tional Hazard ratios from the survival analysis. Exposure
category, including history of injecting drug use, was not
associated with increased hazards for AIDS or death in
survival analysis. Gender was similarly non-predictive.
Older age at diagnosis was a significant predictor of both
AIDS and death in those aged above 35 years. Reduced
initial CD4 cell count was strongly associated with AIDS
and death in adjusted analysis. Higher initial CD4 cell
counts were associated with better outcomes, with the
greatest benefit evident in patients with an initial CD4
cell count above 500 cells/mm3 (HR 0.19 for AIDS CI95
0.11-0.30, p = 0.000; HR 0.32 for death CI95 0.10 - 0.97,
p = 0.044). Ever having recorded a CD4 cell count < 200
cells/mm3 (before or during treatment) was strongly as-
sociated with increased hazards for AIDS (HR 3.61 CI95
2.25 – 5.82, p < 0.001) and death (HR 9.00 CI95 4.04 –
20.02, p < 0.001), while ever having recorded a CD4 cell
count > 500 cells/mm3 (before or during treatment) was
strongly associated with reduced hazards for AIDS (HR
0.30 CI95 0.21 -0.41, p < 0.001) and death (HR 0.08 CI95
0.04 - 0.19, p = 0.000), independent of other covariates.
In unadjusted analysis, having a high (>5 log10) initial
viral load was associated with an increased hazard ratio
for AIDS, and remained significant following adjustment
for other variables (HR 1.79 CI95 1.18 – 2.68, p = 0.006).
There was no relationship between initial viral load and
hazards for death.
Calendar year of ART commencement was a key deter-
minant of outcome. The relationship between calendar
year of ART commencement and AIDS showed reduced
hazards (compared with 1996 – 1999) from 2003 onwards,
while for death the benefit was seen from 2000. While in
unadjusted analysis the risk of AIDS was increased in
those diagnosed with HIV in later years (2000 – 2005),
after adjustment this was not significant. There was no re-
lationship between calendar year of diagnosis and AIDS or
death in adjusted analysis.
Figure 2 compares AIDS and mortality for the follow-up
period 1996 – 2008 between patients with and without a
history of injecting drug use. The Kaplan-Meier estimates
were adjusted for age, year group of diagnosis and initial
CD4 cell count shown to be important covariates in
Table 2. As discussed above, injecting status did not influ-
ence hazard ratios for AIDS or death. In addition, an ana-
lysis was made of PWID only (i.e. heterosexual PWID),
which also found no statistically significant difference
Table 1 Baseline data including demographics by injecting status
Non injectors PWID
No. % No. % Total p
Total 777 100 94 100 871
Exposure category Heterosexual 149 19.2 30 31.9 179
MSM 628 80.8 64 68.1 692
Gender Male 713 91.8 86 91.5 799 p = 0.001**
female 63 8.1 8 8.5 71
transgender 1 0.1 0 0.0 1
Age at first recorded contact with
treatment service
Median, IQR 33.4 30.1 p < 0.001***
Age (years) <25 37 4.8 11 11.7 48
25 - 34 242 31.1 43 45.7 285
35+ 498 64.1 40 42.6 538
Initial CD4 cell count (cells/mm3) Median number
of CD4 records
11 10 p = 0.192
median, IQR 365.5 362 p = 0.461
<200 222 29.2 15 16.3 237 p = 0.506
200 - 349 130 17.1 27 29.3 157
350 - 499 150 19.7 18 19.6 168
500+ 258 33.9 32 34.8 290
Total 760 100.0 92 852
Ever CD4 count < 200 56 7.4 5 8.2 61 p = 0.497
Ever CD4 count > 500 506 66.6 62 10.9 568 p = 0.876
Viral load Median number
of VL records
12 10 3 – 19 p = 0.785
Initial viral load (log10 copies) Median IQR 34100 27150 5700 – 74900 p = 0.759
<4 log 263 34.7 31 10.5 294
4 - 4.99 log 261 34.4 44 14.4 305
5+ log 235 31.0 19 7.5 254
Total 759 100 94 11 853
Year of first recorded contact with
treatment service
1996 - 1999 305 39.3 31 9.2 336
2000 - 2002 236 30.4 30 11.3 266
2003 - 2008 236 30.4 33 12.3 269
Total 777 100 94 10.8 871
Ever started ART 620 79.8 67 9.8 687
Year of Commencement of ART 1996 – 1999 83 133.9 10 10.8 93
2000 – 2002 137 221.0 10 6.8 147
2003 – 2005 183 295.2 18 9.0 201
2006 - 2008 214 345.2 29 11.9 243
Total 620 100 67 9.8 687
Ever AIDS (all) 216 27.8 16 6.9 232 p = 0.026*
Ever AIDS (ever ART) 206 33.2 14 6.4 220 p = 0.040*
Death (all) 52 6.7 4 7.1 56 p = 0.026*
Death (ever ART) 43 6.9 2 4.4 45 p = 0.214
* for p<.05, ** for p<.01, and *** for p<.001.
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Table 2 Hazard Ratios for AIDS and Death for those ever on ART (Adjusted++ and Unadjusted)
AIDS Death
Unadjusted Adjusted Unadjusted Adjusted
HR CI 95 P HR CI 95 P HR CI 95 P HR CI 95 P
Risk group Non injecting drug use Ref Ref Ref Ref
Injecting drug use 0.70 0.39 -1.27 0.242 0.98 0.54 - 1.79 0.944 0.49 0.12 - 2.04 0.328 0.76 0.17 - 3.3 0.709
Heterosexual Ref Ref Ref Ref
MSM 1.24 0.83 -1.86 0.299 1.07 0.7 - 1.63 0.750 1.81 0.71 - 4.59 0.215 1.28 0.48 - 3.42 0.625
Age at diagnosis (years) < 25 Ref Ref Ref Ref
25 - 34 1.04 0.68 – 1.58 0.872 1.81 1.04 - 3.15 0.035* 0.84 0.37 – 1.90 0.677 1.11 0.39 - 3.12 0.850
35+ 1.34 0.88 – 2.04 0.170 3.59 1.88 - 6.85 0.000*** 1.14 0.59 – 2.53 0.737 3.34 0.93 - 12.02 0.065
Age at contact with treatment
service (years)
< 25 Ref Ref Ref Ref
25 - 34 0.87 0.47 – 1.58 0.639 0.46 0.21 - 0.98 0.045* 0.98 0.28 – 3.37 0.969 0.55 0.12 - 2.49 0.441
35+ 0.88 0.49 – 1.57 0.661 0.22 0.1 - 0.51 0.000*** 0.91 0.28 – 3.02 0.881 0.22 0.04 - 1.17 0.075
Initial CD4 count (cells/mm3) <200 Ref Ref Ref Ref
200 - 349 0.18 0.11 -0.30 0.000*** 0.18 0.11 - 0.3 0.000*** 0.39 0.17 - 0.89 0.025* 0.54 0.22 - 1.3 0.167
350 - 499 0.21 0.13 -0.34 0.000*** 0.21 0.13 - 0.34 0.000*** 0.31 0.12 - 0.80 0.015* 0.43 0.16 - 1.17 0.100
500+ 0.19 0.12 -0.29 0.000*** 0.20 0.13 - 0.32 0.000*** 0.17 0.06 - 0.49 0.001*** 0.30 0.1 - 0.93 0.038*
Ever CD4 (cells/mm3) < 200§ 3.06 2.05 -4.56 0.000*** 3.61 2.25 – 5.82 0.000*** 9.41 5.19 - 17.04 0.000*** 9.00 4.04 – 20.02 0.000***
Ever CD4 (cells/mm3) > 500§ 0.32 0.24 -0.43 0.000*** 0.30 0.21 – 0.41 0.000*** 0.09 0.04 - 0.19 0.000*** 0.08 0.04 - 0.19 0.000***
Initial viral load (log10 copies) < 4 log Ref Ref Ref Ref
4 - 4.99 log 1.23 0.83 -1.84 0.307 1.11 0.73 - 1.67 0.632 0.71 0.31 - 1.63 0.422 0.57 0.24 - 1.36 0.208
5 + log 2.60 1.80 -3.77 0.000*** 1.77 1.18 - 2.65 0.005** 1.86 0.94 - 3.67 0.075 1.76 0.81 - 3.85 0.154
Year of diagnosis < 1996 Ref Ref
1996 - 1999 1.45 1.00 -2.10 0.052 1.65 0.83 - 3.27 0.155
2000 - 2002 1.68 1.07 -2.65 0.025* 0.66 0.21 - 2.05 0.471
2003 - 2005 1.71 1.00 -2.94 0.050* 1.14 0.35 - 3.65 0.829
Year of commencement ART < 1996 Ref Ref
1996 – 1999 0.53 0.16 -1.72 0.288 Ref . 0.58 0.14 - 2.52 0.471 Ref .
2000 - 2002 0.30 0.09 -0.99 0.048* 0.58 0.35 - 0.97 0.036* 0.23 0.05 - 1.01 0.051 0.34 0.16 - 0.73 0.006**
2003 – 2005 0.29 0.09 -0.92 0.036* 0.64 0.4 - 1.02 0.062 0.11 0.03 - 0.52 0.005** 0.19 0.08 - 0.42 0.000***
2006 - 2008 0.31 0.10 -1.01 0.051 0.57 0.36 - 0.9 0.017* 0.01 0.00 - 0.09 0.000*** 0.01 0 - 0.08 0.000***
* for p < .05, ** for p < .01, and *** for p < .001.
++In the adjusted analysis, non-significant covariates were dropped, apart from risk group. Gender, age of contact to the treatment clinic and age at ART commencement were excluded from the table as these were
not significant in unadjusted analysis and so not included in adjusted analysis.
§ In adjusted analysis for ‘ever CD4 < or > 500’, initial CD4 count was excluded due to colinearity. The adjusted model for all other results here contains the variable ‘initial CD4 count’ rather than ‘ever














Figure 2 Kaplan-Meier estimates for AIDS and Death by injecting status in Victoria 1996–2008.
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the cohort (data not shown).
Discussion
We found no difference in clinical outcomes for HIV
treatment between patients with and without a history
of injecting drug use in a real-world clinical cohort com-
prising the two largest HIV treatment services in Victoria,
Australia. A number of large studies have examined HIV
treatment among PWID in the post-HAART era. Several
large collaborative cohort studies, as well as a number of
smaller cohorts, have found that PWID have benefited less
from HAARTand continue to progress to AIDS and death
at a faster rate than other risk categories [6,7,13,14].
However, our results are consistent with several previ-
ous studies [11,15-17]. The HERO and ALIVE cohorts
from the east coast of the United States found that
injecting drug use, and its treatment, were not associated
with poorer HIV treatment outcomes compared with non-
injectors among those with higher CD4 counts [15,16]. In
the HERO cohort, commencing HAART at CD4 count of
200 – 350 and > 350 was associated with improved survival
compared with lower CD4 counts, whereas in an analysis
of the ALIVE cohort of PWID, participants with CD4
counts below 200 fared significantly worse than those with
counts above 500. The importance of CD4 cell count in
HIV treatment is well documented [14]. In our study, the
median initial CD4 count did not differ by injecting status
and was reasonably high overall (just over 360); higher
CD4 counts were associated with a reduced risk of AIDSand death, regardless of injecting drug use status. Achiev-
ing a CD4 count of over 500 at one point in time conferred
a substantial decrease in AIDS or death, while ever having
a CD4 count lower than 200 substantially raised the risk of
developing AIDS, irrespective of injecting drug use status.
A recent collaborative cohort study demonstrated that
achieving a CD4 count above 500 was associated with a
mortality rate similar to that of non-HIV infected popula-
tions, and while PWID did not benefit to the same extent,
longer duration of CD4 count above 500 was associated
with improved outcomes, even in PWID. Notwithstanding
this latter finding, our study and others demonstrate the
importance of achieving high CD4 counts in HIV treat-
ment to reduce HIV-related mortality and morbidity [18].
A Spanish study of HIV-infected PWID in a tertiary
hospital setting examined both pre and post-HAART era
HIV survival and found a marked increase in survival in
the post-HAART era, equivalent to non-HIV infected
PWID [17]. This study was conducted in a substance
use treatment setting including opioid substitution ther-
apy (OST) which has been shown to improve adherence
to, and the effectiveness of, HAART [19,20]. A prospective
observational cohort study in British Columbia also found
no difference in mortality rates between HIV-positive
PWID and other groups initiating HAART [11].
Our finding of improved outcomes by calendar year is
consistent with other studies [7,17]. There are a number
of potential reasons for improved HIV treatment out-
comes by calendar year, including a reduction in viro-
logical failure [21] and a shortened duration of HIV
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clinical cohort earlier.
There are a number of limitations to our study. Given
the epidemiology of HIV in Australia, our sample of pa-
tients with a history of injecting drug use was small and
the absolute number of deaths in this group was also
small. Our dataset only included individuals who accessed
services at two urban clinics, and we did not have access
to treatment data from other sites. It has been reported
that some HIV-positive PWID in Melbourne may be re-
luctant to access HIV therapy [22]. Others have reported
that PWID residing near drug using areas are less likely to
access HIV treatment even when it is available [23]. We
did not have reliable data on cause of death, and as others
have demonstrated, deaths in HIV disease are not always
due to HIV infection [15]. Nevertheless, we would expect
substance use deaths to be higher in the PWID group, po-
tentially leading to an increased mortality rate in this
group – which was not the case. In addition, the study
was not able to assess loss to follow-up, so censoring
occurred at the last reported clinical variable or study
endpoint.
We used exposure category at HIV diagnosis as a
population HIV risk classifier, whether or not it reflected
ongoing drug use. We used this proxy as ongoing drug
use data was not available. Although many studies also
use risk category at diagnosis to define an individual’s at-
risk population group [6,7,14-16], this may not always
reflect impact of risk behavior. Potentially, this may have
overestimated the number of PWID, though in which
direction this may have pushed results is contentious.
This study was an analysis of clinical outcomes in a real-
world setting, rather than a stand-alone cohort study. Health
care in Australia operates under a universal Government-
subsidized model, where patients are given care at no charge
at public hospitals and State-funded primary health centers
(such as the Alfred Hospital or Melbourne Sexual Health
Centre). Elsewhere in the community, most general practice
consultations are subsidized by the Federal Government,
with people not on a low income or not receiving social
welfare payments are subject to a small co-payment.
Medication is provided through the National Pharma-
ceutical Benefits Scheme which provides Government
subsidies for medication such that an individual pays a
modest, maximum amount, less if they are receiving
social welfare benefits or are on a pension. These fac-
tors minimize the impact of access to health care issues,
despite our study being done in a real-world context. In
addition to universal health care, adherence to HIV treat-
ment guidelines by HIV clinicians in Australia has been
documented as high [24]. As a consequence, we believe
there is little cost and treatment bias influencing the out-
comes of this study. While our study also compared pa-
tients with a history of injecting drug use and thosewithout, similar to the Canadian study [11], HIV preva-
lence among PWID in Victoria is substantially lower than
in Vancouver/British Columbia. It is not known if or how
this may have impacted on our results.
Conclusion
Our results indicate that in Victoria, patients with a his-
tory of injecting drug use benefit equally well from HIV
treatment as those without a history of injecting drug
use, including MSM and those acquiring HIV from het-
erosexual sexual transmission. In our study, the main
determinants of HIV treatment outcomes remain CD4
cell count, viral load, age and calendar year of HIV
diagnosis.
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